Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Dainippon Sumitomo Pharma Co Ltd Signs License Agreement with Edison Pharmaceuticals for Therapeutic Agents for Mitochondria Disease


Thursday, 28 Mar 2013 07:30pm EDT 

Dainippon Sumitomo Pharma Co Ltd announced that it has signed a research, development and commercial license agreement for the territory of Japan with Edison Pharmaceuticals, Inc., for EPI-743 and EPI-589, therapeutic agents under development by Edison for mitochondrial disease. Under the terms of the agreement, the Company obtains exclusive research, development and commercial rights in Japan for EPI-743 and EPI-589. 

Related Company News

Company Quote

1428.0
20.0 +1.42%
2:00am EDT